Q&A with Advarra’s Client Experience Team Lead Jennifer DeZurik
Client Experience Team Lead Jennifer DeZurik brings both professional and deeply personal connections to Advarra and the world of clinical […]
Blog
How to Select a Clinical Trial Management System
Traditional clinical trial designs often delay progress due to rigid protocols and frequent amendments. Adaptive and platform trial models introduce flexibility and shared infrastructure, reducing startup delays, cutting costs, and enabling sponsors to conduct faster, more efficient research.
Integrating AI to Balance Scientific Rigor and Real-World Feasibility in Clinical Trial Study Design
Traditional clinical trial designs often delay progress due to rigid protocols and frequent amendments. Adaptive and platform trial models introduce flexibility and shared infrastructure, reducing startup delays, cutting costs, and enabling sponsors to conduct faster, more efficient research.
How Sponsors Can Use Adaptive and Platform Trial Models to Reduce Amendments and Accelerate Study Start-Up
Traditional clinical trial designs often delay progress due to rigid protocols and frequent amendments. Adaptive and platform trial models introduce flexibility and shared infrastructure, reducing startup delays, cutting costs, and enabling sponsors to conduct faster, more efficient research.
Q&A with Advarra’s Client Experience Partner Brian Boggs
As a member of Advarra’s client experience team, Brian Boggs plays a pivotal role in helping research clients navigate complex
Enabling Oncology Site Success: Tackling the Barriers That Slow Cancer Research
Oncology clinical trials are becoming increasingly complex, placing new operational and administrative demands on both sponsors and research sites. Protocols
Q&A with Advarra’s Associate Director of Client Services Anna Carnevale
Over the past 14 years, Anna Carnevale, associate director of client services at Advarra, has seen her team grow from
Building Customer Experiences That Lead to More Hope for Patients
Clinical research gives people hope. For some, it’s the chance to hold a new grandchild. For others, it’s walking a
The Impact of ICH E6(R3) on U.S. and Canadian IRBs
Now that FDA has published the ICH E6(R3) Good Clinical Practice (GCP) guidance, aligning early with these requirements can prepare organizations for the future. ICH E6(R3) encourages ethics review committees to more intelligently apply their resources by enhancing efficiency without compromising participant safety or data integrity particularly regarding continuing review, informed consent, decentralized logistics, and data governance. Sponsors partnering with Advarra can be confident that their studies remain regulation-ready on both sides of the border today and E6(R3)-ready for tomorrow.
Advarra’s Perspective on FDA’s Draft AI Guidance: Advancing Responsible Innovation
The U.S. Food and Drug Administration’s (FDA’s) recent draft guidance, “Considerations for the Use of Artificial Intelligence to Support Regulatory
The Story Behind Braid: How the Brand Reflects Advarra’s Vision for Data and AI in Clinical Research
Advarra partnered with PreHealth, a brand growth and experience agency, to create Braid, the identity for Advarra’s data and AI
Are you prepared for ICH E6 (R3)?
The third revision (R3) of the ICH E6 Guideline for Good Clinical Practice represents a significant modernization of global clinical research standards. Research organizations must critically evaluate both their clinical priorities and operational procedures to ensure compliance.